===== AI Summary =====
China's Preimplantation Genetic Testing (PGT) technology is at an internationally advanced level, divided into three categories: PGT-A (aneuploidy screening), PGT-M (monogenic disease diagnosis), and PGT-SR (chromosomal structural rearrangement screening). This technology is suitable for women of advanced maternal age (≥35 years), those with recurrent pregnancy loss (≥2 losses), carriers of chromosomal abnormalities, and families with known monogenic diseases. There are approximately 80 reproductive centers with PGT qualifications in China, with testing accuracy ranging from 95% to 99%. However, attention must be paid to embryonic mosaicism (approximately 5%–10%) and technical limitations. Policy-wise, China has strict access management for PGT and does not allow sex selection for non-medical reasons. It is recommended that patients choose正规 reproductive centers with PGT qualifications and receive professional genetic counseling. PGT cannot guarantee 100% child health, and prenatal diagnosis remains a necessary step.
Clinic Dialogue: "Doctor, I am 38 years old. I had two natural pregnancies before, both resulting in miscarriage around 8 weeks. My husband was found to be a carrier of a balanced chromosomal translocation. Can third-generation IVF solve our problem? How good is the technology in China right now?" — This is a very typical consultation scenario in a reproductive genetics clinic. The woman asking the question looked serious, clutching a stack of test reports in her hand. Her question is precisely the core issue we will systematically address today.
1. What is PGT: Technology Types and Principles
Preimplantation Genetic Testing (PGT), commonly known as "third-generation IVF," is a technology based on in vitro fertilization-embryo transfer (IVF-ET). It involves the biopsy of a few cells from embryos cultured to the blastocyst stage, followed by genetic testing to select embryos with normal chromosomes or genes for transfer. PGT is not a single technology but a collective term for three types:
| Type | Detection Target | Applicable Scenarios |
|---|---|---|
| PGT-A (Aneuploidy Screening) | Chromosomal numerical abnormalities (e.g., Trisomy 21, Trisomy 18, 45,X) | Advanced maternal age, recurrent pregnancy loss, repeated implantation failure |
| PGT-M (Monogenic Disease Diagnosis) | Specific pathogenic gene mutations (e.g., thalassemia, spinal muscular atrophy, hereditary deafness) | Families with known carriers or patients with monogenic diseases |
| PGT-SR (Structural Rearrangement Screening) | Chromosomal structural abnormalities (e.g., balanced translocation, Robertsonian translocation, inversion) | Carriers of chromosomal structural abnormalities |
The detection principles of the three types are all based on next-generation sequencing (NGS) or single nucleotide polymorphism (SNP) arrays, but the testing strategies and data analysis algorithms differ. Currently, all reproductive centers with PGT qualifications in China have adopted NGS platforms, achieving a detection resolution at the Mb level, with some centers capable of detecting microdeletions and microduplications at the sub-chromosomal level.
=========================================================2. Current Status and Level of PGT Technology in China
As of 2025, there are approximately 80 reproductive medicine centers in China approved by the National Health Commission to perform PGT technology, covering most provinces across the country. These centers must pass strict access evaluations and possess a complete disciplinary chain including genetic counseling, embryo biopsy, genetic testing, and prenatal diagnosis.
From a technical perspective, the overall level of PGT in China has entered the international advanced ranks. This is mainly reflected in several aspects:
- Advanced Detection Platforms: NGS technology is widely used, with sequencing depth and coverage comparable to major centers in Europe and America.
- Extensive Biopsy Experience: Over 20 centers perform more than 1000 biopsy cycles annually, with high operational stability and embryo survival rates controlled above 95%.
- Gradually Improving Genetic Counseling System: The state requires all PGT centers to be equipped with trained genetic counselors to provide pre- and post-test counseling for patients.
- Strict Quality Control Standards: The National Health Commission regularly conducts external quality assessments, ensuring the accuracy and consistency of test results.
Practitioner's Observation: As a clinician in a reproductive center, I have been involved in PGT work for over 10 years. Objectively speaking, the gap in PGT testing capability between large reproductive centers in China and internationally renowned laboratories like Reprogenetics in the US and CGC in the UK is now very small. The main difference lies in the coverage of detection databases for some rare genetic diseases, but for common clinical indications, domestic technology is completely reliable.
3. Suitable and Contraindicated Populations for PGT
3.1 Populations Suitable for PGT
- Female age ≥ 35 years: The risk of embryonic aneuploidy increases exponentially with age. PGT-A can screen for euploid embryos, reducing the miscarriage rate.
- Recurrent pregnancy loss (≥ 2 losses): Approximately 40%–60% of early miscarriages are caused by embryonic chromosomal abnormalities. PGT can screen for normal embryos from the source.
- Carriers of chromosomal abnormalities: Such as balanced translocation, Robertsonian translocation, inversion, etc. PGT-SR can identify embryos with normal chromosomal structure.
- Families with known monogenic diseases: Such as thalassemia, spinal muscular atrophy, Huntington's disease, hereditary breast cancer (BRCA), etc. PGT-M can prevent the intergenerational transmission of the disease.
- Repeated implantation failure (≥ 3 attempts): After excluding uterine factors, embryonic chromosomal abnormalities may be one of the causes.
3.2 Populations Not Suitable or Requiring Caution
- Extremely low ovarian reserve (AMH < 0.5 ng/mL, antral follicle count < 3): Few eggs are retrieved, potentially leaving no embryos for biopsy.
- Advanced age with poor embryo developmental potential: For women ≥ 43 years old, even if eggs are retrieved, the proportion that develops to the blastocyst stage and can be biopsied is usually less than 30%.
- Sex selection for non-medical reasons: Explicitly prohibited by Chinese law; no legitimate center performs this.
- Those with excessively high expectations of PGT: Believing PGT can guarantee a 100% healthy child is a misconception that requires full informed consent.
4. Complete PGT Process and Timeline
A complete PGT cycle, from preliminary preparation to transfer, typically takes 2–4 months, depending on the type of testing and the number of embryos. The standardized process is as follows:
| Stage | Specific Content | Approximate Time |
|---|---|---|
| ① Genetic Counseling & Assessment | Collection of family genetic history, genetic testing of proband, analysis of inheritance pattern, assessment of PGT feasibility | 1–2 weeks |
| ② Ovarian Stimulation & Egg Retrieval | Use of antagonist or agonist protocols, ultrasound monitoring of follicle development, egg retrieval 36 hours after HCG trigger | 10–14 days |
| ③ IVF & Embryo Culture | ICSI fertilization, embryo culture to blastocyst stage (Day 5–6) | 5–6 days |
| ④ Embryo Biopsy | Laser-assisted aspiration of 3–5 cells from the trophectoderm of the blastocyst | 1 day |
| ⑤ Genetic Testing | NGS sequencing or SNP array, data analysis, and report generation | 2–4 weeks |
| ⑥ Frozen Embryo Transfer | Selection of euploid/non-carrier embryos for transfer using hormone replacement or natural cycle | 1–2 weeks |
| ⑦ Post-Transfer Follow-up & Prenatal Diagnosis | Pregnancy test 12–14 days post-transfer, ultrasound confirmation at 6–8 weeks, recommendation for amniocentesis verification | Continues into the second trimester |
Easily Overlooked Details: After embryo biopsy, the cell samples need to be rapidly frozen in liquid nitrogen and transported to the testing laboratory. Some centers perform testing locally, resulting in a shorter cycle; if samples need to be sent out, additional logistics time must be allocated. Additionally, test results may show "mosaicism" or "inconclusive" findings (approximately 5%–8%), requiring interpretation by both a genetic counselor and clinician, and possibly recommending re-biopsy or prenatal diagnosis.
5. Differences in Clinical Strategies for Patients of Different Ages
Age is one of the most significant factors affecting PGT outcomes. The euploidy rate, number of eggs retrieved, and embryo developmental potential vary significantly among patients of different ages, requiring corresponding adjustments in clinical strategy.
| Age | Expected Euploidy Rate (PGT-A) | Key Clinical Strategy Points |
|---|---|---|
| < 35 years | 55%–65% | Standard protocol. PGT-A mainly for recurrent miscarriage or genetic disease screening; usually sufficient normal embryos are obtained. |
| 35–39 years | 35%–50% | Consider increasing the number of eggs retrieved; consider cumulative cycles. PGT-A can effectively reduce miscarriage rate. |
| 40–42 years | 15%–30% | Thorough communication regarding the risk of embryo loss is needed; consider backup options like egg or embryo donation. |
| ≥ 43 years | < 10% | PGT-A has limited value. Focus on assessing ovarian response; egg donation is usually the priority. |
From clinical practice, patients over 40 choosing PGT-A need to be psychologically prepared for the possibility of "no euploid embryos." Even with PGT-A, the miscarriage rate in this group remains higher than in younger populations because age also affects endometrial receptivity and mitochondrial function.
=========================================================6. Accuracy and Limitations of PGT
6.1 Testing Accuracy
Technically, the consistency of PGT results (compared with prenatal diagnosis or postnatal verification) ranges from 95%–99%. Among these, PGT-A has the highest accuracy for determining euploidy/aneuploidy, while the accuracy of PGT-M and PGT-SR is limited by the design of testing probes and the completeness of family information.
6.2 Main Limitations
- Embryonic Mosaicism (approximately 5%–10%): Some embryos contain both normal and abnormal cells. The biopsied cells may not represent the entire embryo, leading to false negatives or false positives.
- Risk of Biopsy Damage (approximately 1%–2%): Although laser-assisted biopsy is very precise, it can still affect embryo viability, especially in centers with less experience.
- Testing Failure Rate (approximately 1%–3%): DNA amplification failure, sample contamination, or abnormal data analysis can result in no result.
- Cannot Detect All Genetic Diseases: PGT-M can only detect known specific gene mutations and cannot cover de novo mutations, polygenic diseases, or non-coding region mutations.
- Cannot Replace Prenatal Diagnosis: PGT is a screening tool, not a diagnosis. After pregnancy following transfer, amniocentesis for verification is still recommended at 16–20 weeks of gestation.
7. Differences in PGT Application Between China and Abroad
The differences between China and overseas (USA, Thailand, Japan, Europe, etc.) in the PGT field are mainly reflected in policy management and indication criteria, rather than the technology itself.
| Dimension | China | Overseas (e.g., USA/Thailand) |
|---|---|---|
| Policy Access | Strict access, only about 80 centers approved, requiring periodic review | Relatively relaxed; most IVF centers can perform it, but require CAP/CLIA certification |
| Sex Selection | Strictly prohibited for non-medical reasons | Allowed in some countries (e.g., some US states, Thailand, Cambodia) |
| Indication Scope | Strict medical indications; evidence of genetic disease diagnosis required | Broader; some centers accept applications for "social reasons" |
| Testing Technology | Primarily NGS, synchronized with overseas | NGS + SNP arrays; some centers explore whole genome sequencing |
| Genetic Counseling | Required by the National Health Commission, but professional talent is still insufficient | Mature genetic counselor system; multidisciplinary collaboration is more common |
| Cost (per transfer cycle) | Approximately 50,000–100,000 RMB | Approximately $15,000–$30,000 USD (USA), 50,000–80,000 RMB (Southeast Asia) |
For domestic patients, if the indication is clear, completing PGT at a qualified center in China is a reasonable choice. If it involves indications not permitted in China (such as non-medical sex selection), it is necessary to understand the local legal risks and fully evaluate medical safety.
=========================================================8. Answers to Frequently Asked Questions
Q1: How accurate is PGT? Can it misdiagnose?
The testing accuracy is between 95%–99%, but there is a risk of misjudgment due to mosaicism, technical limitations, etc. It is recommended to routinely undergo prenatal diagnosis (amniocentesis) after transfer for verification, which is the international safety standard.
Q2: How much does PGT cost? Why is there such a big difference?
The total cost for a PGT cycle in China is approximately 50,000–100,000 RMB. Main components: ovarian stimulation medication (10,000–20,000 RMB), egg retrieval surgery and embryo culture (20,000–30,000 RMB), biopsy and testing fees (20,000–40,000 RMB). Cost differences depend on the number of embryos tested, the type of test (PGT-M is usually more expensive than PGT-A), and whether family verification is needed. Some centers also charge genetic counseling fees.
Q3: Does biopsy harm the embryo?
Currently, laser-assisted trophectoderm biopsy is used, performed by experienced embryologists, keeping the damage to the embryo at a very low level. Global data shows that the survival rate of blastocysts after biopsy is over 95%, and the live birth rate after transfer is not significantly different from non-biopsied embryos.
Q4: Does PGT guarantee a 100% healthy child?
No. PGT only tests for specific chromosomal or gene abnormalities. It cannot cover all genetic diseases, de novo mutations, environmental teratogenic factors, or birth defects. Children born after PGT still require routine prenatal check-ups and newborn screening.
Q5: How long does PGT take? Can it be done consecutively?
A complete cycle takes about 2–4 months. If no normal embryos are obtained in the first cycle, another attempt can be made after an interval of 2–3 months. Some patients choose cumulative cycles (multiple ovarian stimulations followed by unified testing) to improve efficiency.
9. Risk Reminders and Doctor's Advice
Risk Reminder: PGT is a mature preventive technology, but it is not a "safety vault." Patients need to be fully aware of the following risks before making a decision: ① Approximately 20%–30% of cycles may have no embryos available for biopsy or all may be abnormal; ② Mosaicism test results may affect embryo selection; ③ There is still a possibility of miscarriage, missed abortion, birth defects, etc., after transfer; ④ Currently, PGT has limited value for detecting mitochondrial diseases, imprinting disorders, and polygenic diseases. Before choosing PGT, it is essential to complete systematic genetic counseling and the informed consent process at a legitimate reproductive center.
Doctor's Advice: If you are considering PGT, the first step is to gather complete information—including the couple's chromosomal karyotype analysis, family genetic disease pedigree, the proband's genetic test report (if available), and previous reproductive history. Take this information to a reproductive center with PGT qualifications, where a reproductive doctor and genetic counselor can jointly assess the indications and expected success rate. Do not make a decision based solely on online information or agency recommendations. Every family's situation is unique and requires an individualized plan.
This content is intended for educational purposes regarding assisted reproductive technology and patient education only and does not constitute medical advice. Please refer to the professional evaluation of a legitimate medical institution for specific diagnosis and treatment plans.
Comments (0)